中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer

文献类型：期刊论文

作者Liu, Xiaochen1,4,5; Wang, Dangge2,4,5; Zhang, Pengcheng2,4,5; Li, Yaping3,4,5
刊名NANO TODAY
出版日期2019-12-01
卷号29页码:19
关键词Nanosized drug delivery systems Nanoparticles Biomimetic vehicles PD-1/PD-L1 blockade Cancer immunotherapy
ISSN号1748-0132
DOI10.1016/j.nantod.2019.100801
通讯作者Wang, Dangge(dgwang@simm.ac.cn) ; Li, Yaping(ypli@simm.ac.cn)
英文摘要Checkpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nanosized drug delivery systems (NDDS) have been fabricated to realize synergistic application with anti-PD drugs for anti-tumor immunity priming or enable targeting delivery of anti-PD drugs with versatile chemical properties. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved anti-PD therapeutic benefits, and discussed the possible directions of the field. (C) 2019 Elsevier Ltd. All rights reserved.
WOS关键词IMMUNE-CHECKPOINT BLOCKADE ; IMMUNOGENIC CELL-DEATH ; ANTITUMOR IMMUNITY ; LIPID NANOPARTICLES ; COMBINATION THERAPY ; LUNG-CANCER ; TUMOR ; ANTI-PD-1 ; PEMBROLIZUMAB ; RADIOTHERAPY
资助项目National Natural Science Foundation of China[81690265] ; National Natural Science Foundation of China[81803444] ; National Natural Science Foundation of China[81521005] ; Strategic Priority Research Program of CAS[XDA12050307] ; Youth Innovation Promotion Association of CAS[2019283] ; Shanghai Sailing Program[19YF1457300]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science
语种英语
WOS记录号WOS:000504503800012
出版者ELSEVIER SCI LTD
源URL[http://119.78.100.183/handle/2S10ELR8/282304]  
专题新药研究国家重点实验室
通讯作者Wang, Dangge; Li, Yaping
作者单位1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
2.Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Shandong, Peoples R China
3.Yantai Univ, Sch Pharm, Yantai 264005, Shandong, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Xiaochen,Wang, Dangge,Zhang, Pengcheng,et al. Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer[J]. NANO TODAY,2019,29:19.
APA Liu, Xiaochen,Wang, Dangge,Zhang, Pengcheng,&Li, Yaping.(2019).Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer.NANO TODAY,29,19.
MLA Liu, Xiaochen,et al."Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer".NANO TODAY 29(2019):19.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。